Covance Gathers Industry Experts to Discuss Implications of REMS on Drug Development
Former FDA Acting Commissioner and other industry experts to offer insight on turning Risk Evaluation and Mitigation Strategies theory into practice.
Princeton, NJ-May 9, 2008-Covance, the world’s largest publicly traded contract research organization, will gather experts from government, pharmaceutical, and legal communities to discuss the impact of Risk Evaluation and Mitigation Strategies (REMS) on drug approvals, healthcare providers, patients, and patient safety on May 29, 2008, from 10:00am–4:30pm at the Marriott Hotel and Conference Center in Princeton, NJ.
Dr. Lester Crawford, former acting commissioner of the Food and Drug Administration (FDA), will be the keynote speaker at the complimentary symposium designed for pharmaceutical and biotechnology executives in risk management, safety, regulatory affairs, and medical affairs. Panelists also include pharmaceutical, legal and scientific experts specializing in areas ranging from drug approvals, post-market commitments, risk management, and REMS as they relate to the Food and Drug Administration Amendments Act (FDAAA) of 2007.
“This event will help provide pharmaceutical and biotechnology executives with practical solutions for applying REMS to their drug development programs,” said Hani Zaki, general manager, periapproval services, Covance. “Our goal is to provide education, interpretation, and application of REMS to help attendees prepare for any anticipated implications on drug approvals, patient selection, and safety.”
FDAAA has been called the most sweeping reform of drug legislation in decades, and for the first time grants the FDA authority to enforce post-marketing agreements through fines and other forms of regulatory controls. The FDA may now also require new post-marketing study commitments (PMCs) or demand other risk-mitigation steps at any point post-approval should new safety signals emerge.
Pharmaceutical and biotechnology executives involved in risk management, safety, regulatory affairs, and medical affairs can register for the complimentary symposium via e-mail at rsvp@covance.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
